PeploBio

What PeploBio does

PeploBio is a UK-headquartered contract research organization (CRO) and clinical diagnostic laboratory that provides biomarker, immune monitoring, and clinical trial support services to pharmaceutical and biotechnology companies. Founded in 2021 and based in Guildford with a regional office in Raleigh, North Carolina, the company offers an integrated service platform spanning flow cytometry, immunoassays (including ELISA and BD FACSLyric platforms), genomics (qPCR, Sanger sequencing, CRISPR, DNA sequencing), clinical trial project management, companion diagnostics development, biospecimen procurement, and a broad diagnostic testing catalog. Regulatory consulting services cover FDA, IVDR, UKCA, CTDA, and Quality Management System establishment for IVD manufacturers.

The company's product portfolio is anchored by two proprietary assays that differentiate it from generic CROs. The MicroCLOT Assay detects and quantifies fibri(nogen) amyloid microclots for research in Long Covid, ME/CFS, and chronic inflammatory disease. The GLP-1 HRAMS Assay, co-developed with Kingston Analytical Services Toxicology (KAST) at Kingston University London, provides high-resolution accurate mass spectrometry quantification of GLP-1 receptor agonists in plasma and whole blood, supporting pharmacokinetic profiling, adherence monitoring, and exposure-response modeling for the rapidly growing incretin-based metabolic therapeutics market. KAST is UKAS-accredited to ISO/IEC 17025, lending the partnership technical credibility.

PeploBio generates revenue primarily through professional services CRO engagements (project-based clinical trial support, assay development and validation, biospecimen procurement, regulatory consulting) supplemented by subscription-based diagnostic testing delivered through the Partner Hub program, which offers tiered options including digital marketing support, kits, and account management. The go-to-market combines direct enterprise sales to pharma and biotech clients with a partner channel for diagnostic testing distribution. In 2022, Life Sciences Review recognized the company as the Top Clinical Laboratory Services Company in the UK. The firm is privately held with no disclosed institutional funding and operates as an independent, founder-controlled entity.

Name

PeploBio

Legal name

PeploBio

Website

https://peplobio.co.uk

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

PeploBio is a UK-based contract research organization and clinical diagnostic laboratory providing biomarker, immune monitoring, clinical trial support, and regulatory consulting services to pharmaceutical, biotechnology, and IVD manufacturers across UK and US operations.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) and Clinical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAGAAAA

Clinical CROs (Phase I–IV)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAD

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAE

Central Laboratory & Clinical Trial Testing CROs

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAL

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

Keywords

• Contract research organization
• Biomarker assay development
• Clinical trial services
• Immune monitoring services
• Diagnostic laboratory services

Headquarters

HQ city

Guildford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Services: CRO services including project management, assay development and validation, companion diagnostics (CDx), and clinical trial support for pharmaceutical companies across phase 1-4 trials.
2. Diagnostic Testing Services: Comprehensive diagnostic testing laboratory offering dozens of tests in oncology, infectious disease, serology, and metabolic disease through partner hub with tiered subscription options.
3. Regulatory Consulting Services: Consulting services for IVDR, FDA approval, UKCA certification, CTDA regulatory approval, and Quality Management System establishment.
4. Biospecimen Procurement: High-quality biospecimen procurement through a diverse network of collection sites, supporting clinical trial patient recruitment and biobank access.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

PeploBio is a specialised Contract Research Organization (CRO) and clinical diagnostic laboratory that provides integrated biomarker assay development, immune monitoring, genomics, and clinical trial support services to pharmaceutical and biotechnology companies. Its core commercial offerings centre on two proprietary assays (MicroCLOT and GLP-1 HRAMS), flow cytometry and immunoassay platforms, companion diagnostics development, biospecimen procurement, and regulatory consulting across FDA, IVDR, UKCA, and CTDA frameworks.

Product overview

PeploBio is a specialized Contract Research Organization (CRO) providing clinical trial and diagnostic services through two strategically located sites in the UK and US. The company operates as a unified service platform combining immune monitoring (Flow Cytometry Services, Immunoassays), clinical trial support (Clinical Trial Management, Biospecimen Procurement, Companion Diagnostics), diagnostic testing (Diagnostic Testing Services, Tests A-Z), and regulatory consulting (IVDR, FDA, UKCA, CTDA, QMS). The portfolio centers on two proprietary assays: the MicroCLOT Assay for fibri(nogen) amyloid microclot detection used in Long Covid and chronic disease research, and the GLP-1 HRAMS Assay for GLP-1 receptor agonist quantification developed with Kingston University. Supporting services include Genomics Services (qPCR, CRISPR, DNA sequencing), Performance Evaluation, and assay development and validation for exploratory through Phase 2 clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• MicroCLOT assay: Proprietary assay for detection and quantification of fibri(nogen) amyloid microclots, transforming research in Long Covid, ME/CFS, and chronic inflammatory disease.
• GLP-1 HRAMS Assay

Products and services

• Flow Cytometry Services Comprehensive flow cytometry services including assay development, validation, and multiple immune monitoring assays (basophil activation, cell proliferation, MDSC assays, receptor occupancy, cell enumeration, cellular phenotyping, immune checkpoint analysis) for pharmaceutical and biotech clients.
• Immunoassays Immunoassay development services including ELISA, peptide and antibody screening, cellular phenotyping, receptor occupancy, and TBNK analysis, integrated with broader immune monitoring and clinical trial support workflows.
• Clinical Trial Management Integrated clinical trial project management services that oversee drug and device development programs end-to-end, including assay development, validation, and companion diagnostics support for pharmaceutical and biotech sponsors.
• Genomics Services Genomic services including qPCR, Sanger sequencing, CRISPR, gene silencing, targeted gene expression analysis, and DNA sequencing for clinical research and biomarker applications.
• Diagnostic Testing Services Comprehensive clinical diagnostic testing laboratory offering dozens of tests in oncology, infectious disease, serology, and metabolic disease, delivered through direct enterprise sales and the Partner Hub tiered subscription program.
• Performance Evaluation Services Performance evaluation services for IVD manufacturers including analytical performance studies, clinical performance evaluation, and usability studies to support regulatory submissions.
• IVDR Services Regulatory consulting services for In Vitro Diagnostic Regulation (IVDR) compliance required for marketing in vitro diagnostic medical devices within the European Union.
• FDA Approval Services Consultant services for FDA regulatory strategy and approval processes for US market entry of medical devices and diagnostics.
• UKCA Certification Services UKCA marking assessment and certification services for medical devices manufactured in Great Britain to access the UK market.
• CTDA Regulatory Approval Coronavirus Test Device Approval (CTDA) preparation and submission services for COVID-19 test devices seeking UK market access.
• Quality Management System (QMS) Establishment Quality management system (QMS) establishment services for medical devices, including policies, procedures, and processes to ensure product safety and efficacy.
• Biospecimen Procurement Biospecimen procurement and sourcing services through a diverse network of collection sites, providing high-quality samples in line with quality and bioethical standards, supporting clinical trial patient recruitment and biobank access.
• Companion Diagnostics (CDx) Companion diagnostic (CDx) development services that facilitate regulatory approval of companion diagnostics alongside pharmaceutical and biotech therapeutics.
• MicroCLOT Assay Proprietary assay for the detection and quantification of fibri(nogen) amyloid microclots, used for research in Long Covid, ME/CFS, and chronic inflammatory disease.
• GLP-1 HRAMS Assay Quantitative high-resolution accurate mass spectrometry (HRAMS) assay for detection and measurement of GLP-1 receptor agonists in plasma and whole blood, designed for pharmacokinetic profiling, adherence monitoring, and dose-response modeling in metabolic and obesity-related therapy research. Developed in partnership with Kingston Analytical Services Toxicology (KAST) at Kingston University London.

Quantifiable outcome

• Advanced GLP-1 receptor agonist quantification with high specificity detection in complex biological matrices
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• KAST (Kingston Analytical Services Toxicology) at Kingston University LondoncoreStrategic or Co-development PartnerStrategic partnership to develop a quantitative HRAMS (high-resolution accurate mass spectrometry) assay for detection and measurement of GLP-1 receptor agonists in biological matrices. KAST is a UKAS-accredited ISO/IEC 17025 laboratory providing specialized high-resolution accurate mass spectrometry services. This partnership enables pharmaceutical and clinical research programs with advanced analytical solutions for metabolic therapeutics including GLP-1 and dual incretin therapies.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Emerging players

• Bio-Techne: Life science tools and diagnostic reagents provider with growing clinical trial assay services footprint (e.g., ProteinSimple, ExoDx). Comparable as a related emerging player in biomarker assay development and immunoassay platforms for clinical research.

Broad incumbents

• Medpace: Mid-to-large CRO providing full-service clinical development. Comparable as a scaled competitor in clinical trial project management, central lab services, and biomarker/CDx development.
• ICON plc: Global CRO and bioanalytical services provider. Overlaps with PeploBio's clinical trial management, bioanalytical assay development, and regulatory consulting offerings at much larger scale.
• Eurofins Scientific: Global bioanalytical, central laboratory, and clinical testing services group. Overlaps with PeploBio's bioanalytical, genomics, and clinical trial testing services as a scaled incumbent across multiple geographies.
• SGS Health Science: Global clinical research and bioanalytical services provider. Comparable as a broad-incumbent CRO offering bioanalytical, clinical trial, and biospecimen-related services for pharma and biotech clients.

Direct peers

• Celerion: Clinical CRO specializing in early-phase clinical pharmacology and bioanalytical services. Highly comparable to PeploBio's Phase 1–2 clinical pharmacology, PK/PD, and bioanalytical assay work, including method development and validation for clinical trials.
• Frontage Laboratories: CRO providing bioanalytical, biomarker, CMC, and clinical services with strong LC-MS/MS and immunoassay capabilities. Directly comparable to PeploBio's bioanalytical CRO positioning and assay development work.
• Worldwide Clinical Trials: Mid-sized global CRO with strong bioanalytical and clinical pharmacology capabilities. Comparable to PeploBio's mid-sized CRO service profile across Phase 1–4 trials and specialty bioanalytical assays.
• Pharmaron: Integrated CRO offering lab-based services across discovery, preclinical, clinical bioanalysis, and biologics. Comparable to PeploBio's CRO model combining bioanalytical assay development, flow cytometry/immunoassays, and clinical trial support.
• BioAgilytix Labs: Bioanalytical and biomarker CRO with deep immunoassay, flow cytometry, and LC-MS/MS capabilities. Directly comparable to PeploBio's immunoassay, flow cytometry, and biomarker assay development offerings for biopharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/peplobio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PeploBio